Cell Therapeutics, Inc. (CTIC) Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group
11/20/2009 6:35:25 AM
More...
|
Cell Therapeutics, Inc. (CTIC) Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45%
11/5/2009 8:15:42 AM
More...
|
Cell Therapeutics, Inc. (CTIC): Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma Overview of Phase II-III Clinical Trials will be Presented at International Lymphoma Meeting
10/22/2009 9:11:22 AM
More...
|
Cell Therapeutics, Inc. (CTIC) Reports Outcome of Annual Meeting of Shareholders
10/21/2009 9:17:02 AM
More...
|
Cell Therapeutics, Inc. (CTIC) Annual Meeting of Shareholders Scheduled for Tuesday, October 20, 2009
10/16/2009 8:55:26 AM
More...
|
Cell Therapeutics, Inc. (CTIC): OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer
10/1/2009 8:56:16 AM
More...
|
Cell Therapeutics, Inc. (CTIC) Applies for European Orphan Drug Designation for Pixantrone in Aggressive Non-Hodgkin's Lymphoma (NHL)
9/29/2009 9:20:12 AM
More...
|
Cell Therapeutics, Inc. (CTIC) Finalizes Asset Sale and Closure of Italian Branch, Saves $20 Million in 2010 Annual Operating Expenses
9/28/2009 8:32:49 AM
More...
|
Cell Therapeutics, Inc. (CTIC) Pulls EU Application for Lung Drug Opaxio
9/24/2009 7:17:22 AM
More...
|
Cell Therapeutics, Inc. (CTIC) Added to the The Nasdaq Stock Market -- New York OMX Global Biotechnology Index
9/22/2009 8:33:07 AM
More...
|
|